Literature DB >> 25492937

Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells.

Samik Basu1, Britany Hubbard1, Ethan M Shevach2.   

Abstract

CD4(+)CD25(+)Foxp3(+) Tregs have a diminished capacity to activate the PI3K/Akt pathway. Although blunted Akt activity is necessary to maintain Treg function, the consequences of this altered signaling are unclear. Glut1 is a cell-surface receptor responsible for facilitating glucose transport across plasma membranes, whose expression is tightly coupled to costimulatory signals and Akt phosphorylation. Freshly isolated human Tregs were unable to up-regulate Glut1 in response to TCR and costimulatory signals compared with Tconv. Consequently, the ability of Tregs to use glucose was also reduced. Introduction of Foxp3 into Tconv inhibited Akt activation and Glut1 expression, indicating that Foxp3 can regulate Glut1. Finally, pharmacologic activation of Akt in Tregs can induce Glut1, overcoming the effects of Foxp3. Together, these results illustrate the molecular basis behind differential glucose metabolism in Tregs. © Society for Leukocyte Biology.

Entities:  

Keywords:  autoimmunity; lymphocyte; metabolism; signal transduction

Mesh:

Substances:

Year:  2014        PMID: 25492937      PMCID: PMC4304425          DOI: 10.1189/jlb.2AB0514-273RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  23 in total

1.  The CD28 signaling pathway regulates glucose metabolism.

Authors:  Kenneth A Frauwirth; James L Riley; Marian H Harris; Richard V Parry; Jeffrey C Rathmell; David R Plas; Rebecca L Elstrom; Carl H June; Craig B Thompson
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

Review 2.  Fuel feeds function: energy metabolism and the T-cell response.

Authors:  Casey J Fox; Peter S Hammerman; Craig B Thompson
Journal:  Nat Rev Immunol       Date:  2005-11       Impact factor: 53.106

3.  Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells.

Authors:  Natasha K Crellin; Rosa V Garcia; Megan K Levings
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

4.  Flow cytometry-based methods for studying signaling in human CD4+CD25+FOXP3+ T regulatory cells.

Authors:  Natasha K Crellin; Rosa V Garcia; Megan K Levings
Journal:  J Immunol Methods       Date:  2007-06-11       Impact factor: 2.303

5.  PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.

Authors:  Patrick T Walsh; Jodi L Buckler; Jidong Zhang; Andrew E Gelman; Nicole M Dalton; Devon K Taylor; Steven J Bensinger; Wayne W Hancock; Laurence A Turka
Journal:  J Clin Invest       Date:  2006-08-17       Impact factor: 14.808

6.  Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis.

Authors:  Naoshi Sugimoto; Takatoku Oida; Keiji Hirota; Kyoko Nakamura; Takashi Nomura; Takashi Uchiyama; Shimon Sakaguchi
Journal:  Int Immunol       Date:  2006-06-13       Impact factor: 4.823

7.  B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs.

Authors:  Jens M Chemnitz; Anthony R Lanfranco; Inbal Braunstein; James L Riley
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

8.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

9.  The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function.

Authors:  Andrew N Macintyre; Valerie A Gerriets; Amanda G Nichols; Ryan D Michalek; Michael C Rudolph; Divino Deoliveira; Steven M Anderson; E Dale Abel; Benny J Chen; Laura P Hale; Jeffrey C Rathmell
Journal:  Cell Metab       Date:  2014-06-12       Impact factor: 27.287

Review 10.  FOXP3: of mice and men.

Authors:  Steven F Ziegler
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

View more
  34 in total

Review 1.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

Review 2.  Metabolic Barriers to T Cell Function in Tumors.

Authors:  Ayaka Sugiura; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1.

Authors:  Hongbao Guo; Yang Nan; Yingwei Zhen; Yahui Zhang; Liyun Guo; Kai Yu; Qiang Huang; Yue Zhong
Journal:  Tumour Biol       Date:  2016-07-31

4.  PI3K-Akt signaling controls PFKFB3 expression during human T-lymphocyte activation.

Authors:  Helga Simon-Molas; Claudia Arnedo-Pac; Pere Fontova; Anna Vidal-Alabró; Esther Castaño; Ana Rodríguez-García; Àurea Navarro-Sabaté; Núria Lloberas; Anna Manzano; Ramon Bartrons
Journal:  Mol Cell Biochem       Date:  2018-02-12       Impact factor: 3.396

5.  Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways.

Authors:  N A Zwang; R Zhang; S Germana; M Y Fan; W D Hastings; A Cao; L A Turka
Journal:  Am J Transplant       Date:  2016-05-23       Impact factor: 8.086

Review 6.  Fine tuning of immunometabolism for the treatment of rheumatic diseases.

Authors:  Jillian P Rhoads; Amy S Major; Jeffrey C Rathmell
Journal:  Nat Rev Rheumatol       Date:  2017-04-06       Impact factor: 20.543

Review 7.  Treg programming and therapeutic reprogramming in cancer.

Authors:  Mariela A Moreno Ayala; Zehui Li; Michel DuPage
Journal:  Immunology       Date:  2019-04-29       Impact factor: 7.397

Review 8.  Dysfunctional T cell metabolism in the tumor microenvironment.

Authors:  Kathryn E Beckermann; Stephanie O Dudzinski; Jeffrey C Rathmell
Journal:  Cytokine Growth Factor Rev       Date:  2017-04-23       Impact factor: 7.638

9.  Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.

Authors:  Valerie A Gerriets; Rigel J Kishton; Marc O Johnson; Sivan Cohen; Peter J Siska; Amanda G Nichols; Marc O Warmoes; Aguirre A de Cubas; Nancie J MacIver; Jason W Locasale; Laurence A Turka; Andrew D Wells; Jeffrey C Rathmell
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

Review 10.  The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease.

Authors:  Gerwyn Morris; Michael Berk; Andre Carvalho; Javier R Caso; Yolanda Sanz; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-06-27       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.